Wiley.com

Mass Spectra of Designer Drugs

HOBOKEN, NJ - April 30th, 2018 Wiley-VCH launches 2018 edition of Mass Spectra of Designer Drugs

Wiley-VCH announced the publication of the 2018 edition of Mass Spectra of Designer Drugs, the most extensive mass spectral reference library compiled by Dr. Peter Rösner and extensively reviewed by the mass spectral experts Dr. Giselher Fritschi and Thomas Junge. The 2018 edition features the addition of over 1,300 new mass spectra and over 700 new, unique compounds in over 30 different classification groups. This includes over 415 fentanyls, 1,042 synthetic cannabinoids, and 344 opiates.

Mass Spectra of Designer Drugs is the single most comprehensive reference for the identification of synthetic drugs and analog variants. It is an essential tool for helping labs meet the challenges of the opioid and syntehics epidemic. This mass spectral library is the largest collection of chemical signatures of NPS and drugs of abuse in the world, by factors of 11x to 190x. The rapid development of these drugs poses serious challenges to current policies, procedures, and methods of detection and identification of these substances.

Key Features:

Mass Spectra: 26,459
Chemical structures: 26,459
Unique compounds: 20,381
Opiates: 344
Fentanyles: 415
Cannibimimetics: 930
Canniboids: 112
Measured Kovats Indices: 17,114
Average Quality Index/Spectrum (QI): 949.4
  • Mass Spectra: 26,459
  • Chemical structures: 26,459
  • Unique compounds: 20,381
  • Opiates: 344
  • Fentanyls: 415
  • Cannibimimetics: 930
  • Canniboids: 112
  • Measured Kovats Indices: 17,114
  • Average Quality Index/Spectrum (QI): 949.4

The 2018 edition is compatible with leading manufacturer formats such as NIST MS Search, Agilent .L (Chemstation, MassHunter, OpenLab), Thermo Xcalibur, Chromeleon, and Shimadzu GCMS Solution. MS of Designer Drugs 2018 is avialable from instrument manufacturers and directly from Wiley.


Media Contact:
sciencenewsroom@wiley.com
Follow us on Twitter @WileyNews